Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$3.27
-0.3%
$3.32
$2.70
$4.72
$626.29M0.86662,202 shs553,477 shs
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
$9.98
+1.7%
$0.00
$0.00
$0.00
$159.65M1.1837,983 shs21,884 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$8.35
-2.2%
$8.33
$2.21
$19.71
$582.95M0.45911,990 shs501,927 shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$10.37
-5.1%
$10.10
$6.42
$29.60
$550.54M1.08226,927 shs283,932 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
0.00%+1.55%+1.08%-8.91%-13.26%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
+1.73%+0.91%+27.13%+81.45%+92.66%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
0.00%-13.29%-4.73%+202.54%-29.36%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
0.00%-6.24%+3.75%-4.51%-53.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
2.1737 of 5 stars
3.51.00.00.01.82.50.6
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
1.8793 of 5 stars
3.51.00.00.00.01.70.6
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2.6585 of 5 stars
3.52.00.00.00.05.00.6
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
1.6482 of 5 stars
3.50.00.00.01.43.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
3.00
Buy$5.5068.20% Upside
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
3.00
Buy$13.0030.26% Upside
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.00
Buy$17.50109.58% Upside
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
3.00
Buy$30.83197.33% Upside

Current Analyst Ratings Breakdown

Latest ELTX, ABUS, PHAT, and TYRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2025
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $13.00
7/1/2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $17.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
5/21/2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$33.00
(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$6.17M101.51N/AN/A$0.51 per share6.41
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
$2.30M69.43N/AN/A($1.03) per share-9.69
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$55.25M10.55N/AN/A($3.71) per share-2.25
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/A$6.78 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
-$51.90M-$6.950.00N/AN/AN/AN/A-185.70%N/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/7/2025 (Estimated)
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$86.48M-$1.63N/AN/AN/AN/A-26.90%-25.54%8/6/2025 (Estimated)

Latest ELTX, ABUS, PHAT, and TYRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.02N/AN/AN/A$2.21 millionN/A
8/7/2025Q2 2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$0.76N/AN/AN/A$35.58 millionN/A
8/6/2025Q2 2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.53N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million
5/13/2025Q1 2025
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
-$0.67-$0.87-$0.20-$0.87N/AN/A
5/8/2025Q1 2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.49-$0.47+$0.02-$0.47N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
0.04
6.01
6.01
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/A
1.83
1.83
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
3.58
3.54
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/A
22.78
22.78

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
43.79%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
35.03%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
84.14%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
20.30%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
50.90%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
23.00%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
15.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
90191.53 million152.65 millionOptionable
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/A16.00 million7.86 millionNot Optionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11069.81 million53.76 millionOptionable
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2053.09 million45.02 millionOptionable

Recent News About These Companies

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$3.27 -0.01 (-0.30%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.28 +0.00 (+0.15%)
As of 08/1/2025 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Elicio Therapeutics stock logo

Elicio Therapeutics NASDAQ:ELTX

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$8.35 -0.19 (-2.22%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$8.40 +0.05 (+0.59%)
As of 08/1/2025 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Tyra Biosciences stock logo

Tyra Biosciences NASDAQ:TYRA

$10.37 -0.56 (-5.12%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.37 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.